CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers will present results from four studies related to kidney transplant at the 2015 American Transplant Congress (ATC), being held May 2-6, 2015, in Philadelphia. The presentations will include data from two eculizumab (Soliris®) studies, one in the prevention of acute antibody-mediated rejection (AMR) in sensitized deceased-donor kidney transplant recipients, and another in adult patients with atypical hemolytic uremic syndrome (aHUS) with or without a history of kidney transplant.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
